STERIS plc reported its fiscal 2026 third‑quarter results, posting total revenue of $1.5 billion, a 9% year‑over‑year increase and 8% growth in constant‑currency terms. The company’s revenue growth was driven by a 9% rise in Healthcare revenue to $1.1 billion, an 11% jump in Applied Sterilization Technologies (AST) revenue to $286.6 million, and a 6.9% increase in Life Sciences revenue to $145.8 million. These gains offset modest headwinds from tariff and inflationary pressures that weighed on cost of revenue.
Net income from continuing operations reached $192.9 million, translating to $1.96 per diluted share, while adjusted net income climbed to $249.4 million, or $2.53 per diluted share. The adjusted EPS of $2.53 matched consensus estimates of $2.53, a beat of $0.00 against the highest estimate of $2.56. The beat was largely attributable to disciplined cost management and a favorable mix shift toward higher‑margin segments, which helped offset the impact of tariff‑related cost increases.
Segment operating income rose across the board: Healthcare operating income climbed to $258.1 million, AST to $129.2 million, and Life Sciences to $61.8 million. The operating‑income gains were driven by stronger volume and pricing in Healthcare and AST, while Life Sciences benefited from a higher mix of contract services. Gross margin compression, however, was noted in some reports, reflecting higher raw‑material and labor costs, but the company’s operating margin expansion indicates effective cost control and pricing power.
Management highlighted that the quarter’s performance was “strongly supported by the continued execution of our commercial teams and a diversified portfolio.” CEO Dan Carestio noted that “high single‑digit revenue growth combined with cost discipline is allowing us to deliver meaningful earnings per share growth despite increased tariff headwinds.” The company reaffirmed its fiscal 2026 outlook, maintaining revenue growth guidance of 8‑9% and adjusted EPS guidance of $10.15 to $10.30, unchanged from prior guidance. This steady outlook signals confidence in sustained demand and cost management.
Investors reacted cautiously, with after‑hours trading showing a decline of roughly 2.5% to 3.6%. The muted response was driven by a slight EPS miss against the higher consensus estimate and concerns over a contraction in gross margins, despite the company’s revenue beat and maintained guidance. The market’s focus on margin trends underscores the importance of cost control in a tariff‑heavy environment, while the steady outlook suggests management believes the company can navigate the headwinds and continue to grow its recurring revenue base.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.